RxDoctor Payments Data

Lawrence Rajan, MD

Cardiovascular Disease · Eau Claire, WINPI 1295985497

Payments from drug & device makers

$12,899in general payments, 2019–2025

Across 108 payments — averaging $119.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • AstraZeneca$4K
  • Abbott$3K
  • Philips North America LLC$1K
  • Actelion Pharmaceuticals US, Inc.$108
  • Novartis$103
  • plus $440 from 9 others

What the payments were for

  • Speaking & faculty fees$3,70029%
  • Travel & lodging$6,88053%
  • Food & beverage$2,30018%
  • Education$190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,899 in reported general payments places this provider in the 75th percentile of 322 cardiovascular disease providers in Wisconsin.

See all cardiovascular disease providers in Wisconsin

Medicare billing

Part B allowed, 2024
$108,621
Medicare patients
1,022
Services billed
2,056

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban209$221,265
JardianceEmpagliflozin48$45,704
XareltoRivaroxaban15$24,379
EntrestoSacubitril/Valsartan27$23,922
BrilintaTicagrelor25$16,953
ClopidogrelClopidogrel Bisulfate102$1,338
Metoprolol Succinate91$1,147
Atorvastatin Calcium131$1,085
Ranolazine ErRanolazine13$894
Rosuvastatin Calcium51$598
Metoprolol Tartrate140$598
Isosorbide Mononitrate ErIsosorbide Mononitrate31$562
Losartan Potassium54$561
Diltiazem 24hr Er (Cd)Diltiazem Hcl16$542
Lisinopril58$490

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$61$24,37915 claims
NovartisEntresto$103$23,92227 claims
AstraZenecaBrilinta$3,877$16,95325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 322 cardiovascular disease providers in Wisconsin.

Other cardiovascular disease in Eau Claire

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →